Behcet's disease: a new target for anti-tumour necrosis factor treatment

نویسندگان

چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Anti-Tumour Necrosis Factor-α Therapy in Crohn’s Disease

Crohn’s disease is a chronic, relapsing, inflammatory disease of the gastro-intestinal tract. Manifestations of the disease may be severe, and lead to long-term therapy with a variety of medications and/or surgery. There are two main classifications of the disease, including the relapsing-remitting chronic active variety, and the penetrating or fistulising variety. Tumour necrosis factor-alpha ...

متن کامل

Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients.

BACKGROUND Ulcerative colitis (UC) and Crohn's disease can sometimes relapse and be refractory to standard treatment following orthotopic liver transplantation (OLT) despite post-transplantation immunosuppressive therapy. AIM To evaluate the efficacy and safety of anti-tumour necrosis factor (anti-TNF) agents for the management of IBD following OLT. METHODS We reviewed the records of patien...

متن کامل

Tumour necrosis factor and Crohn's disease.

The production of several pro-inflammatory cytokines is increased in inflammatory bowel diseases (IBD). Experimental models of IBD have further defined the importance of specific cytokines for the induction of mucosal inflammation, by using specific neutralising antibodies, or by silencing cytokine genes in mice by using homologous recombination (knockout mice).' 2 Several therapeutic strategie...

متن کامل

Anti-tumour necrosis factor (anti-TNF) in the treatment of juvenile idiopathic arthritis-associated uveitis

Results Of the 16 patients, 10 were treated with etanercept (62.5%), 1 with adalimumab (6.25%), and 5 (31.2%) with infliximab. Notably, two cases of uveitis were associated with use of etanercept. In 5 patients (31.2%) the antiTNF was changed because of lack of efficacy and/or side effects to another one (in 4/5 adalimumab). Ten patients had a complicated uveitis (cataract in 5). The number of ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Annals of the Rheumatic Diseases

سال: 2002

ISSN: 0003-4967

DOI: 10.1136/ard.61.suppl_2.ii51